Drugs & Targets FoundationOne CDx test receives FDA approval as companion diagnostic to identify NTRK fusions in solid tumors for Vitrakvi October 30, 2020Vol.46 No.41
Drugs & Targets FDA approves cobas EGFR Mutation Test v2 as the first companion diagnostic test for expanded EGFR TKI therapies in NSCLC October 30, 2020Vol.46 No.41
Drugs & Targets CPI-613 receives FDA orphan drug designation for soft tissue sarcoma October 30, 2020Vol.46 No.41
Drugs & Targets EQRx licenses two immune checkpoint inhibitors from CStone Pharmaceuticals. October 30, 2020Vol.46 No.41
Drugs & Targets StrataNGS genomic profiling receives Medicare coverage in patients with advanced solid tumors October 30, 2020Vol.46 No.41
Clinical Roundup USPSTF draft guideline: Colorectal cancer screening should start at 45 October 30, 2020Vol.46 No.41
Clinical Roundup Study: Racial disparities in treatment NSCLC persist despite gains October 30, 2020Vol.46 No.41
Clinical Roundup Winship study shows increased DFS rates for men with prostate cancer October 30, 2020Vol.46 No.41
Clinical Roundup New York Proton Center joins RadComp clinical trial evaluating proton v. photon therapy in non-metastatic breast cancer October 30, 2020Vol.46 No.41
